PHARMACEUTICAL COMPOSITION COMPRISING 1-(3-CYANO-1-ISOPROPYL-INDOL-5-YL)PYRAZOLE-4-CARBOXYLIC ACID

The present invention relates to a pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazol-4-carboxylic acid or a pharmaceutically acceptable salt thereof, and a method of treating or preventing a hyperuricemia-related disease using the same, and the pharmaceutical compositio...

Full description

Saved in:
Bibliographic Details
Main Authors GWAK, HEEMIN, MIN, JI YOUNG, KIM, MIN HEE, SEO, JUNG YOUN, KIM, JUNYU, MUNE, JUNE SIK, LEE, JIEUN, SHIN, SEONG HYE
Format Patent
LanguageEnglish
French
Published 22.12.2022
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to a pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazol-4-carboxylic acid or a pharmaceutically acceptable salt thereof, and a method of treating or preventing a hyperuricemia-related disease using the same, and the pharmaceutical composition of the present invention may effectively reduce the blood uric acid concentration in a patient with a hyperuricemia-related disease. La présente invention concerne : une composition pharmaceutique comprenant de l'acide 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylique, ou un sel pharmaceutiquement acceptable de celui-ci ; et une méthode de prévention ou de traitement de maladies associées à l'hyperuricémie l'utilisant. La composition pharmaceutique selon la présente invention peut réduire efficacement la concentration d'acide urique dans le sang d'un patient atteint d'une maladie liée à l'hyperuricémie.
Bibliography:Application Number: CA20223221017